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Abstract
Objectives The prevalence of rheumatoid arthritis (RA)
and its current treatment practices in Japan are poorly
documented. Therefore, we examined these factors in a
Japanese health insurance database.
Methods We analyzed reimbursement data provided by
health insurance societies for 1 million individuals,
including healthy individuals, registered from January
2005 to June 2011. Changes in treatments were determined
in 320 thousand individuals originally registered in 2005.
The treatment patterns were compared with those of the
Institute of Rheumatology, Rheumatoid Arthritis (IORRA)
cohort managed by Tokyo Women’s Medical University.
Results The estimated prevalence of RA was 1.24 million
(1.0 % of the Japanese population), excluding suspected
cases, and 706 thousand (0.6 %) in a sensitivity analysis.
Seventy-nine percent of patients were treated for RA.
Methotrexate was used by 27 % of patients. In 2005, 5 %
of patients were prescribed methotrexate at [8 mg/week,
which increased to 13 % in 2011. These rates were lower
than those in the IORRA cohort.
Conclusions Our results indicate that the prevalence of
RA in Japan is somewhere between 0.6 and 1.0 %. Con-
sidering that methotrexate is infrequently used, the imple-
mentation of aggressive treatment regimens such as the
‘Treat to Target’ strategy is important to achieve tight
control of RA in Japan.
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Introduction
The treatment of rheumatoid arthritis (RA) has advanced
markedly over the last 10 years [1]. The introduction of
methotrexate (MTX), the foundation for RA treatment, and
biological products targeting specific molecules that induce
or aggravate the inflammation associated with RA, have
increased the likelihood of achieving clinical remission,
and potentially structural and functional remission.
In Japan, MTX was approved for the treatment of RA in
1999, some 10 years later than its approval in the United
States (US) and Europe. At that time, the dose of MTX was
limited to 8 mg/week. In addition, MTX was not originally
approved as a first-line treatment in Japan. Consequently,
MTX has been underused for many years in Japan. In 2011,
the Ministry of Health, Labour and Welfare approved MTX
doses of up to 16 mg/week and its use as a first-line drug,
partly based on actual treatment practices [2]. MTX is now
widely recommended as a foundation of RA treatment in
internationally recognized treatment guidelines [3, 4].
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Of concern, however, is that relatively few epidemio-
logical studies aimed at determining the prevalence of and
treatment practices for RA have been performed in Japan
[5–7], unlike in the US and Europe. The studies performed
to date focused on specific hospitals or on a specific region
of Japan, and did not examine the nationwide prevalence of
RA in Japan. Therefore, the true prevalence of RA in Japan
has not been adequately investigated. In addition, despite
recent advances in treatment options for RA, there have
been no nationwide studies aimed at examining the adop-
tion of the newer treatments in actual clinical practice,
including patients under the care of non-specialists,
although some cohort studies have been conducted in
limited medical institutions [2, 8–11].
Therefore, we conducted a study with the following
aims: (1) to determine the current prevalence of RA in
Japan and (2) to examine current treatment practices. To
achieve these aims, we conducted analyses of reimburse-
ment data covering *1 million people (0.84 % of the
Japanese population) who were members of Japanese
health insurance societies. In this study, we determined the
estimated prevalence of RA in Japan and examined the
changes in treatment patterns over time, particularly of
MTX, which is recommended as the anchor drug in the
current treatment strategies for RA. We also compared the
treatment patterns identified in this reimbursement data-
base with those of the Institute of Rheumatology, Rheu-
matoid Arthritis (IORRA) cohort, which is managed by
Tokyo Women’s Medical University [1, 2, 8–11]. The
objective of this comparison with the IORRA cohort was to
determine whether the treatment practices applied in gen-
eral clinical practice are similar to those applied in a spe-
cialist center focusing on RA.
Methods
Study database
This analysis was conducted using reimbursement data
provided by the Japan Medical Data Center Co., Ltd.
(JMDC) [12], which was purchased by Pfizer, Japan.
JMDC, through contracts with multiple Japanese health
insurance societies (as of October 2012, there are 20 health
insurance societies contributing to the JMDC database), has
accumulated reimbursement data from 1,067,782 people,
including healthy individuals aged \75 years. In Japan,
there is a separate medical insurance system for individuals
aged C75 years; thus, when patients reach the age of
75 years, they are automatically removed from health
insurance societies. As a result, the JMDC database only
includes patients aged \75 years and patients within
1 month of their 75th birthday; therefore, the number of
patients aged 75 years or older in the database is very low.
In this database, personal information is encrypted irre-
versibly, information is recorded under patient names, and
medical consultation information can be tracked for each
patient in a chronological order, even if the patient attends
multiple medical institutions or following hospital transfers.
Wherever possible, diagnoses are recorded in the JMDC
database using International Classification of Diseases
(ICD) version 10 codes. Considering its size, representa-
tiveness for Japan, and the scope of data recorded, it is
possible to use the data to estimate the national incidence of
a specific disease. JMDC started collecting data for 320
thousand people in 2005, which increased to 600 thousand
people from 2008, to 750 thousand people in 2009, and to 1
million people in 2010. All patients are continuously
tracked in the database, which contains data for up to
7 years, as of January 2012, depending on when each
patient was first registered. In this analysis, we used data
registered in 2005 and 2010.
The IORRA cohort is a prospective observational cohort
of RA patients treated at the Institute of Rheumatology,
Tokyo Women’s Medical University from October 2000
[1, 2, 8–11]. Patients with RA who fulfilled the American
College of Rheumatology 1987 criteria for RA [13] were
registered, and their information and data were collected
biannually (in April and October). Informed consent was
obtained from each patient at each visit. Over 98 % of the
RA patients attending our institute participated in the study
each time. For the purpose of this study, we used data reg-
istered between April 2005 and October 2011 to match the
period recorded by the reimbursement database. The dis-
tribution of patients aged C75 years in the IORRA cohort
was low, and ranged from 9.4 % in April, 2005, to 12.3 % in
October, 2011. To allow for direct comparisons between the
JMDC data and the IORRA cohort, we limited the analyses
of the IORRA cohort to patients aged\75 years.
Estimation of the prevalence of RA and prescription
rates of drugs for RA
Using reimbursement data for 1 million people registered
in 2010, we estimated the prevalence of RA and the
number of patients prescribed any drugs for RA. We then
estimated the prevalence of RA and drug prescription for
the period July 2010 to June 2011. The diagnosis of RA
and suspected RA was based on the disease name stated on
health insurance claim forms, as recorded in the database
using ICD 10 codes (M05.9, RA with a positive serological
reaction, detail unknown; M06.0, RA with a negative
serological reaction; M06.8, RA specified in other types;
M06.9, RA, detail unknown). Using the JMDC database,
the prevalence of RA was estimated by calculating the
proportion of patients with a confirmed or suspected
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diagnosis of RA for sex and 1-year age groups. We then
multiplied the obtained values by the number of males or
females recorded in the Japanese Population Census (Sta-
tistics Bureau, Ministry of Internal Affairs and Communi-
cations; http://www.e-stat.go.jp/SG1/estat/GL08020103.do?
_xlsDownload_&fileId=000005147291&releaseCount=2)
for each 1-year age group (total population, 128 million).
Since the study population consisted of subscribers to
health insurance societies, and included relatively few
elderly individuals, this analysis was limited to patients aged
C16 to \75 years. We excluded patients aged \16 years
because they should be diagnosed with juvenile idiopathic
arthritis (JIA) rather than rheumatoid arthritis. Drugs used
to treat RA included oral NSAIDs (non-steroidal anti-
inflammatory drugs), NSAID patches and oral steroids, and
drugs listed in the anatomical therapeutic chemical (ATC)
classification system were identified from the reimburse-
ment data. Regarding MTX, only the brand (i.e., Rheu-
matrex) and generic products specifically indicated for the
treatment of RA, class M01C, were identified (Table 1). As
a sensitivity analysis we excluded patients using NSAID
patches alone and patients prescribed other drugs only
once.
Changes over time in the prescription of drugs for RA
The prevalence of RA from January 2005 to June 2011 was
calculated using data for 320 thousand individuals aged
\75 years. Then, the proportions of patients prescribed any
drugs for RA and with specific drugs were tabulated for
every 6-month period. The values recorded in both 6-month
periods in the preceding year were used to examine the
changes in prescription rates over time. The proportion of
patients prescribed MTX of all patients prescribed disease-
modifying anti-rheumatic drugs (DMARDs), including
MTX, was also determined. In the IORRA cohort, the drugs
that the patients actually took in the 6 months before each
visit were reported by each patient using questionnaires.
Changes over time in the dose of MTX
The number of prescriptions for each dose level of MTX
between January 2005 and June 2011 was tabulated using
data for 320 thousand people for every half year, and values
for the preceding 1 year were calculated to examine changes
over time. Since the medical receipts did not always specify
MTX dose, or the dose was unclear, only prescription receipts
were analyzed. The changes in MTX dose over time were
based on the actual doses prescribed rather than the number of
patients with RA. For example, a patient with three individual
prescriptions of three different doses of MTX (e.g., 6, 8 and
10 mg/week MTX) was included in three separate analyses,
one for each dose. The data from prescription sheets lacking
the required dose (including those with an unclear dose) were
not recorded in the JMDC database. We did not restrict this
analysis by age. In the IORRA cohort, the MTX dose taken by
the patient in the 6 months before each visit was reported by
each patient using questionnaires.
Results
Prevalence of and treatment practices for RA in Japan
The estimated prevalence of RA from July 2010 to June
2011 relative to the total population of Japan aged\75 years
was determined based on the disease names recorded on
health insurance claim forms and recent census data. The
total number of RA patients aged C16 to \75 years old
(excluding suspected RA) was 5,344 (3,868 females; 1,476
males) (Supplemental Table). The results of this analysis,
and types of treatments used, are summarized in Table 2.
The number of RA patients was estimated as 2.29 million if
suspected cases are included; as a sensitivity analysis, if
suspected cases were excluded, the number of RA patients
was estimated as 1.24 million. Thus, the estimated preva-
lence of RA was 1.0 % of the entire Japanese population
aged C16 to \75 years.
Overall, three times as many females as males were
diagnosed with RA (913 thousand, 74 % vs 328 thousand,
26 %, of 1.24 million). The age distribution was as follows:
C16 to \20 years: 0.3 %, 4 thousand; 20 to \30 years:
1.5 %, 18 thousand; 30 to\40 years: 5.2 %, 65 thousand; 40
to\50 years: 9.7 %, 121 thousand; 50 to\60 years: 22.5 %,
279 thousand; 60 to\70 years: 43.3 %, 538 thousand; and
70–74 years: 17.5 %, 217 thousand. The estimated number
Table 1 Treatments available for rheumatoid arthritis in Japan
Drug class Drugs available and ATC code, where applicable




Topical products for joint and muscular pain [M02]
Oral steroids Corticosteroids for systemic use, plain [H02A2]
Corticosteroids for systemic use, combinations
[H02B]
DMARDs Actarit, auranofin, salazosulfapyridine, bucillamine,
lobenzarit disodium, sodium aurothiomalate,





Tocilizumab, adalimumab, infliximab, etanercept
and abatacept
ATC anatomical therapeutic chemical, NSAID non-steroidal anti-




of patients with RA and under treatment for this condition
between July 2010 and June 2011 was 983 thousand.
In terms of treatment, 79 % of all patients with RA
(excluding suspected RA) had been prescribed a drug for
RA during the indicated period. The most commonly pre-
scribed drug classes in this population were oral NSAIDs
(55 % of patients), NSAID patches (47 %), DMARDs
(including MTX; 40 %) and oral steroids (30 %). MTX
was prescribed to 27 % of patients and only 8 % were
prescribed biological products. As a sensitivity analysis, we
excluded patients using NSAID patches alone. Among
patients with a definitive diagnosis of RA who were pre-
scribed a drug only once (defined as a prescription filled in
just 1 month in the 12-month analysis period), 8 % were
using NSAID patches alone and 14 % of patients were
prescribed drugs other than NSAID patches (oral NSAIDs
only, 10 %; oral steroids only, 1 %; oral NSAIDs and oral
steroids, 1 %; and other medications, 2 %). For the purpose
of this analysis, we used the following assumption. Sub-
tracting the 8 % of patients prescribed only NSAID patches
and 14 % of patients prescribed other drugs for only
1 month from the 79 % of patients treated with any drug,
left 57 % of the patients (706 thousand patients) or
approximately 0.6 % of the Japanese population.
Changes in the prescribing practices for drugs for RA
over time
We next determined changes in the prescription rates of
drugs for RA. The results shown in Fig. 1a and b indicate
that the prescription of biological products and MTX
increased over time, whereas no marked changes were
observed for the other drugs for RA. As shown in Fig. 2a,
the proportion of patients using MTX of all patients pre-
scribed a DMARD increased from 34 % in December 2005
to 63 % in June 2011, indicating increased reliance on
MTX as a DMARD in Japan.
The prescription rates of MTX and biological products
also increased in the IORRA cohort (Fig. 1c), although
both were used more frequently in the IORRA cohort than
in the reimbursement database. The proportion of patients
using MTX of all patients prescribed a DMARD increased
substantially, from 64 % in 2005 to 83 % in 2011
(Fig. 2b). Another difference between the IORRA cohort
and the reimbursement database is that the use of oral
steroids, oral NSAIDs, and DMARDs (excluding MTX)
decreased over time (Fig. 1c).
Changes in MTX doses over time
Until 2011, the maximum approved dose of MTX in
Japan was 8 mg/week. As shown in Fig. 3a, at the start of
data collection in 2005, *95 % of patients were being
prescribed MTX at doses of B8 mg/week, while 5 %
were receiving doses [8 mg/week. The prescription rates
of high doses of MTX have increased progressively over
time; as of June 2011, 13 % were receiving doses [8 mg/
week. An increase in MTX dose was also evident in the
IORRA cohort, although the dose was much higher
(Fig. 3b). In the IORRA cohort, the proportion of patients





Composite 1a (%) Composite 2b (%)
Prevalence of RAc
Including suspected RA 2,287 2,224–2,367 – –
Excluding suspected RA 1,241 1,194–1,306 100 –
Treatments receivedd
Any drug 983 941–1,043 79 100
Oral NSAIDs 681 646–734 55 69
NSAID patches 580 548–630 47 59
Oral steroids 371 346–417 30 38
DMARDs (including MTX) 500 471–548 40 51
DMARDs (excluding MTX) 266 245–306 21 27
MTX 329 308–371 27 34
Biological products 95 86–125 8 10
RA rheumatoid arthritis, CI confidence interval, NSAID non-steroidal anti-inflammatory drug, MTX methotrexate
a Of all patients with documented RA
b Of all patients on treatment for RA
c Estimates were based on the disease name recorded on health insurance claim forms
d Estimates were based on the drugs stated on health insurance claim forms
Mod Rheumatol
123
taking MTX at a dose[8 mg/week was 20 % in 2005 and
42 % in 2011.
Discussion
Health insurance databases, which have been established
using reimbursement claims data, provide a powerful tool
for health-economic analyses that reflect daily clinical
practice in the target population [14–16]. In the US and
Europe, numerous studies of health insurance subscribers
have already been conducted, focusing on RA [17–22].
These studies have analyzed the proportion of patients
receiving specific drugs, the doses used, treatment contin-
uation rates, and medical expenses [23, 24]. In Japan,
similar studies have been conducted in the fields of oste-
oporosis [25] and Parkinson’s disease [26]. We think that
such analyses will become increasingly common, and will
help to better understand current clinical practice in Japan
and in other countries. Therefore, we took advantage of the
large sample size of the health insurance database to esti-
mate the prevalence and treatment patterns of RA in Japan.
In this analysis, the number of patients diagnosed with
RA based on prescriptions was 1.24 million and the num-
ber of patients prescribed anti-RA drugs was 983 thousand.
After subtracting the number of patients prescribed only
NSAID patches and those prescribed drugs other than
NSAID patches only once, we were left with 706 thousand
patients. The values of 1.24 million, 983 thousand, and 706
thousand correspond to 1.0, 0.8, and 0.6 % of the Japanese
population, respectively.
In early studies that did not include age limits, The
Ministry of Health, Labor and Welfare of Japan [27] esti-
mated that there were 336 thousand individuals with RA
who were continuously receiving medical care at clinics or
hospitals. Shichikawa et al. [6] estimated the prevalence of
Fig. 2 a Proportion of patients receiving methotrexate of all patients treated with disease-modifying antirheumatic drugs. b Results of the
IORRA cohort. The number of patients aged \75 years in the IORRA cohort ranged from 4,312 in 2005 to 5,001 in 2011
Fig. 1 Changes over time in the proportion of patients prescribed
specific classes of drugs for RA. a Of all patients diagnosed with RA.
b Of all patients being treated for RA. c Results of the IORRA cohort.
The number of patients aged\75 years in the IORRA cohort ranged
from 4,312 in 2005 to 5,001 in 2011
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RA in Wakayama Prefecture, Japan, and reported that it
reached a peak in 1969 (0.54 %, 95 % CI 0.17–0.87 %)
and was lowest in 1996 (0.17 %, 95 % CI 0.03–0.31 %).
Meanwhile, the estimated prevalence of RA ranged from
0.5 to 1 % in a systematic review of studies conducted in
Western countries [28] including the US (1.07 %) and
northern Europe (0.50 %, 95 % CI 0.44–0.80 %), although
slightly lower rates were reported in southern Europe
(0.33 %, 95 % CI 0.31–0.50 %) and in developing
countries (0.35 %, 95 % CI 0.24–0.36 %). Although the
estimated prevalence of 0.6 % in our study is a conserva-
tive estimate and was limited to individuals aged C16
to\75 years, it corresponds to the upper limit in Japan and
lower limits in Western countries. Therefore, we might
expect the prevalence rate to be slightly higher than that
reported in earlier studies.
However, we should consider that methodological dif-
ferences (e.g., analysis of health insurance/reimbursement
data and epidemiological questionnaires using randomized,
clustered samples) prevent direct comparisons of the
results of the studies described above.
The second objective of this study was to examine the
current status of RA treatment in Japan, and changes in
recent years. Over the past 10 years, several biological
products have been introduced into clinical settings, and
the ‘Treat to Target’ approach is increasingly being adop-
ted since its inception in 2010 [1, 29]. As a result, there is
increasing demand for achieving tight control of the dis-
ease, requiring aggressive treatment strategies, as well as
changes in the regulatory environment. Moreover, since
MTX, which is the anchor drug for RA treatment, is now
indicated for use as a first-line treatment for RA, and the
maximum approved dose has been increased to 16 mg, it
seems likely that RA treatment has undergone marked
changes in recent years. Changes in RA treatment practices
in Japan have been evaluated by several research groups,
including the IORRA cohort managed by the Institute of
Rheumatology, Tokyo Women’s Medical University [1,
11]. In that study, as in the present study, the proportions of
patients treated with MTX and biological products, have
steadily increased over time. However, as of June 2011 [1],
70 % of patients were receiving MTX, of which 38 %
received doses exceeding 8 mg/week. The proportion of
patients receiving biological products was 15 % [1].
Notably, those values were higher than those obtained in
the present study. However, this may be due to differences
in data collection. In the present study, doses were
extracted from a health insurance database, which recorded
the number of prescriptions and the prescribed doses. By
comparison, in the IORRA study, patients kept a record of
the actual doses taken, which also allowed the authors to
assess compliance rates. Therefore, the results of the two
studies should not be compared directly. One may expect
the actual doses to be taken to be smaller than the pre-
scribed doses, resulting in a bias toward a smaller differ-
ence in dose between the two studies. Considering that the
differences were quite substantial, we think that aggressive
treatment strategies for RA are being adopted in medical
institutions specialized for treating RA, such as Tokyo
Women’s Medical University, but less so in general clin-
ical practice. In this context, it is interesting to see that the
use of oral steroids, oral NSAIDs, and DMARDs, other
than MTX, has decreased over time in the IORRA cohort
but not in the reimbursement database. These results
Fig. 3 a Changes in methotrexate dose over time. b Results of the IORRA cohort. The number of patients in the IORRA cohort ranged from
4,312 in 2005 to 5,001 in 2011
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suggest that nationwide educational programs are needed
to increase awareness and implementation of recent treat-
ment strategies in Japan.
The results of this study should be interpreted with some
caution, taking into account the limitations of the study. We
analyzed a database of 1 million people belonging to health
insurance societies in Japan. Therefore, the database may
not fully represent the general population of Japan, as
elderly individuals are less likely to be members of such
societies. Considering the database includes relatively few
elderly patients, the treatment situation described here may
not reflect that of actual clinical practice. Meanwhile, rela-
tively few younger patients were diagnosed with RA using
this database, most likely reflecting the higher incidence of
JIA diagnosis rather than RA itself. It is also possible that
some of the patients aged\20 years with RA actually had
JIA, which may result in an overestimation of the prevalence
of RA. However, as there were only 45 patients with RA
aged \20 years the impact of this is likely to be minimal.
Nevertheless, to minimize the impact of this, we excluded
patients aged\16 years from the analysis, as this age-group
is more likely to have JIA. Finally, the ‘quality’ of diagnosis
may be a limiting factor, as some patients were ‘diagnosed’
with RA in this study on the basis of diagnosis written in
claim forms, while other patients were assumed to have RA
on the basis of prescription for drugs that are routinely used
for RA. However, as 8 % of patients were only prescribed
NSAID patches and 14 % of patients received other drugs
for only 1 month, it is possible that these patients were given
a nominal diagnosis of RA so that they could be prescribed
drugs specific for RA. To help track disease names and
diagnoses, all diseases were recorded in the database using
ICD-10 codes, which were used wherever possible.
It is important to consider that the designs of various
studies may limit direct comparisons. Generally, the
prevalence of a disease such as RA is ascertained either by
surveys of patients or through analysis of health insurance/
reimbursement data. Patient surveys assess the patient’s
main disease/injury, without taking into account compli-
cations. Furthermore, such studies may result in bias
towards patients under active treatment; patients with low
disease activity, other more serious diseases, or cognitive
limitations, for example, are less likely to respond to such
surveys [30]. Additionally, such studies may involve rela-
tively small numbers of patients identified through clus-
tered sampling. Considering these limitations of traditional
patient surveys, there is an increasing shift towards anal-
yses of larger databases managed by public and private
health insurance providers. These databases, including the
JMDC, can record data for a much larger cohort of patients
than is generally possible with patient surveys, along with
longitudinal data for individual patients. Additionally, the
databases can record information on specific diagnoses,
treatments prescribed, duration of treatment, and changes
in prescribing behavior over time [14, 15]. The resulting
data can be used in the context of diagnostic, etiologic,
prognostic, and intervention research [14, 15], as well as
aiding coverage and reimbursement decisions [16]. As
described above, however, health insurance databases may
be subject to other forms of bias. In particular, private
health insurance societies may include a relatively small
number of elderly patients, which may result in an under-
estimation of diseases that predominantly affect elderly
individuals, such as RA. In addition, some drugs may be
prescribed for off-label uses. Direct assessment of co-
morbidities may also be difficult using health insurance
databases [31]. Therefore, care must be taken when
assessing diseases based on prescribed drugs alone.
In conclusion, the current study revealed that the prev-
alence of RA in Japan is quite high (1.0 %, 1.24 million
individuals aged C16 to \75 years). Based on this result
and other sensitivity analyses, we suggest that the preva-
lence of RA in Japan is somewhere between 0.6 and 1.0 %.
The use of MTX doses [8 mg/week and biological prod-
ucts is steadily increasing, consistent with the shift towards
aggressive treatment paradigms. However, the rates are
still quite low, suggesting that educational programs are
needed to raise awareness of the need for aggressive
treatment regimens, such as the ‘Treat to Target’ strategy,
to improve outcomes of Japanese patients with RA.
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